SYRACUSE, N.Y. — Upstate Medical University announced it has launched a new clinical trial of an antibody that could be used in the fight against COVID-19.
The Institute for Global Health and Translational Science is seeking healthy individuals to participate in this clinical trial to assess how the body reacts to an antibody created by SAB Biotherapeutics.
Upstate Medical is one of just two sites nationwide testing the antibody.
(Sponsored)
“Borderline” Overtime Exemptions Require Careful Analysis and Precautionary Measures
Q: We have an employee who we believe is properly classified as exempt from receiving overtime under the Fair Labor Standards Act (FLSA) but it is a “borderline” case. In
What is Fiducuary Liability and how does it affect you and your business?
Managing a company’s insurance needs can be complex and stressful. It doesn’t need to be when adding certain specialty insurance products, like fiduciary liability insurance. It protects the sponsoring company;
The phase-one study is seeking healthy adults 18 to 60 years old who have not participated in another clinical trial within 30 days of enrollment and have no history of COVID-19. Participants must also agree to not participate in any other trials during the study period.
Compensation and parking are provided and participants will not incur any expenses for participating, Upstate Medical said.
Upstate Medical on Aug. 10 dosed its first patient in the study and is “actively” screening participants. In the blinded study, some individuals will receive a placebo while others will receive the antibodies.
The process
The study involves two initial screening visits followed by eight outpatient clinic visits over 90 days. Participants will receive an infusion of the antibody during the first clinic visit, which will take between 60 and 90 minutes. They are asked to stay at the site for a minimum of six hours after the initial infusion. Participants are required to record any symptoms for seven days after receiving the infusion.
The study is in conjunction with Sioux Falls, South Dakota–based SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies without the need for human serum, according to the company.
Study visits will take place in the clinical research unit of the Institute for Human Performance on the Upstate Medical University campus.
Individuals interested in participating in the study may call (315) 464-9869 or email trials@upstate.edu for more information.
